96 related articles for article (PubMed ID: 30124372)
1. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
Leuk Lymphoma; 2019 Mar; 60(3):668-674. PubMed ID: 30124372
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
3. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2018 Oct; 21(10):1036-1040. PubMed ID: 30071761
[TBL] [Abstract][Full Text] [Related]
4. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
6. Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia.
Kropf P; Barnes G; Tang B; Pathak A; Issa JP
Leuk Lymphoma; 2016; 57(4):935-41. PubMed ID: 26480922
[TBL] [Abstract][Full Text] [Related]
7. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
8. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
J Med Econ; 2014 Feb; 17(2):89-98. PubMed ID: 24188054
[TBL] [Abstract][Full Text] [Related]
9. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines.
Jabbour E; Makenbaeva D; Lingohr-Smith M; Lin J
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):797-802. PubMed ID: 26603185
[TBL] [Abstract][Full Text] [Related]
10. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
Ector GICG; Govers TM; Westerweel PE; Grutters JPC; Blijlevens NMA
Leuk Lymphoma; 2019 Jun; 60(6):1485-1492. PubMed ID: 30668187
[TBL] [Abstract][Full Text] [Related]
11. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
12. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
Menzin J; Lang K; Earle CC; Glendenning A
Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
Klil-Drori AJ; Yin H; Azoulay L; Del Corpo A; Harnois M; Gratton MO; Olney HJ; Delage R; Laneuville P; Mollica L; Busque L; Assouline SE;
Cancer; 2019 Feb; 125(4):618-625. PubMed ID: 30423211
[TBL] [Abstract][Full Text] [Related]
15. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
16. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
18. [Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study].
Kulikov SM; Vinogradova OIu; Chelysheva EIu; Tishchenko IA; Galaĭko MA; Lazareva OV; Senderova OM; Pepeliaeva VM; Meresiĭ SV; Luchinin AS; Ovsepian VA; Miliutina GI; Gavrilova LV; Avdeeva LB; Neverova AL; Turkina AG
Ter Arkh; 2014; 86(7):24-30. PubMed ID: 25314774
[TBL] [Abstract][Full Text] [Related]
19. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
[TBL] [Abstract][Full Text] [Related]
20. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]